A phase II study evaluating Avastin in combination with Zybrestat demonstrated increased progression-free survival in recurrent ovarian cancer.
A retrospective analysis of a phase III study found that talimogene laherparepvec reduced the size of injected tumors and non-injected metastatic melanoma tumors that had metastasized to other parts of the body.
An independent data monitoring committee recommended that the phase III METLung study be stopped due to a lack of clinically meaningful efficacy, following an interim analysis.
The European Committee for Medicinal Products for Human Use delivered a positive opinion for a two-dose schedule for the Gardasil HPV vaccine in boys and girls ages 9 through 13.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
NCI scientists found that a daily aspirin regimen may reduce the risk of ovarian cancer by 20 percent, but say further research is needed before clinical recommendations can be made.
Five years after having proton therapy for early- and intermediate-risk prostate cancer, 99 percent of men are living cancer-free and with excellent quality of life, according to a study. Three-quarters of those with high-risk prostate cancer are also disease-free.
Researchers concluded that the MammaPrint genomic breast cancer test can accurately stratify a woman's breast cancer risk for up to 25 years after she is first diagnosed with the disease.
Research on lymphatic mapping and sentinel-node biopsy has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over traditional “watch and wait” techniques.
Two studies presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium suggested that positive HPV status could be used as a biomarker indicator related to improved survival.
